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Abstract
Background: The effects of spinal implants on dose distribution have been studied for conformal treatment plans.
However, the dosimetric impact of spinal implants in stereotactic body radiotherapy (SBRT) treatments has not
been studied in spatial orientation. In this study we evaluated the effect of spinal implants placed in sawbone
vertebra models implanted as in vivo instrumentations.
Methods: Four different spinal implant reconstruction techniques were performed using the standard sawbone
lumbar vertebrae model; 1. L2-L4 posterior instrumentation without anterior column reconstruction (PI); 2. L2-L4
anterior instrumentation, L3 corpectomy, and anterior column reconstruction with a titanium cage (AIAC); 3. L2-L4
posterior instrumentation, L3 corpectomy, and anterior column reconstruction with a titanium cage (PIAC); 4. L2-L4
anterior instrumentation, L3 corpectomy, and anterior column reconstruction with chest tubes filled with bone
cement (AIABc). The target was defined as the spinous process and lamina of the lumbar (L) 3 vertebra. A
thermoluminescent dosimeter (TLD, LiF:Mg,Ti) was located on the measurement point anterior to the spinal cord.
The prescription dose was 8 Gy and the treatment was administered in a single fraction using a CyberKnife®
(Accuray Inc., Sunnyvale, CA, USA). We performed two different treatment plans. In Plan A beam interaction with
the rod was not limited. In plan B the rod was considered a structure of avoidance, and interaction between the
rod and beam was prevented. TLD measurements were compared with the point dose calculated by the treatment
planning system (TPS).
Results and discussion: In plan A, the difference between TLD measurement and the dose calculated by the TPS
was 1.7 %, 2.8 %, and 2.7 % for the sawbone with no implant, PI, and PIAC models, respectively. For the AIAC
model the TLD dose was 13.8 % higher than the TPS dose; the difference was 18.6 % for the AIABc model. In plan
B for the AIAC and AIABc models, TLD measurement was 2.5 % and 0.9 % higher than the dose calculated by the
TPS, respectively.
Conclusions: Spinal implants may be present in the treatment field in patients scheduled to undergo SBRT. For
the types of implants studied herein anterior rod instrumentation resulted in an increase in the spinal cord dose,
whereas use of a titanium cage had a minimal effect on dose distribution. While planning SBRT in patients with
spinal reconstructions, avoidance of the rod and preventing interaction between the rod and beam might be the
optimal solution for preventing unexpectedly high spinal cord doses.
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Introduction
Bone is the third most common site of metastatic can-
cer, and bone metastasis occurs in approximately 70 %
of patients with metastatic breast cancer and prostate
cancer [1]. The axial skeleton is the most frequently af-
fected site [2–4]. Proper treatment of bone metastasis
requires interdisciplinary care, and includes analgesics,
corticosteroids (particularly in patients with spinal cord
compression), hormonal therapy, bisphosphonates, sur-
gery, chemotherapy, radiotherapy (RT), radiopharmaceu-
ticals, or any combination of these.
Conventional external beam RT provides significant
palliation of painful bone metastasis in 50–80 % of pa-
tients, but only 33 % of patients achieve complete pain
relief at the treated site [5]. Studies have shown equiva-
lent pain relief for various RT protocols, such as 30 Gy
in 10 fractions, 24 Gy in 6 fractions, 20 Gy in 5 fractions,
and a single 8-Gy fraction [6, 7]; however, the need for
re-irradiation because of recurrent pain was higher in
the single fraction arm, as compared to the fractionated
protocols (20 % vs. 8 %). Hartsell et al. [7] evaluated
patients with spinal metastasis separately and only
61 % of patients experienced partial or complete pain
relief at 1 month post-treatment. Such studies high-
light the need for improved outcomes in patients with
spinal metastasis. Increasing the RT dose to the target
is a legitimate option for increasing control rate; how-
ever, spinal cord tolerance is the limiting factor for
increasing the delivered dose using conventional RT
techniques.
Stereotactic body radiotherapy (SBRT) is an innovative
treatment option for spinal metastasis. SBRT facilitates
the delivery of a higher dose of radiation precisely to the
target while limiting the dose to the spinal cord with
rapid dose fall-off. Clinical studies on SBRT reported
that it is an efficacious technique for pain control, with a
rapid onset of response (as early as within 24 h) [8–10].
Additional experience with SBRT for spinal metastasis
suggests a dose-response relationship, with an increase
in pain relief—particularly at doses ≥16 Gy [10]. The
major concern is the dose to the spinal cord, and the
spinal dose constraint of 10 Gy to 10 % of the spinal
cord defined in a maximum of 6 mm above and below
the radiosurgery target is most commonly reported [11].
As SBRT is increasingly used in RT clinics for spinal
metastases, patients with implants in the treatment field
are often encountered. The spatial orientation of the im-
plants in the vertebra is alike in patients with same im-
plantation techniques. When a cage is used for vertebral
column reconstruction the minimum distance between
the cage and the spinal cord is 5 mm. The distance be-
tween the rods and the cord is more than 2 cm. The
present study aimed to determine the dosimetric effect
of spinal implants on the dose received by the spinal
cord, in a sawbone model where the configuration of the
implants could be simulated as in vivo.
Materials and Methods
In this study 4 different spinal implant reconstruction
models were employed on the standard sawbones of
lumbar vertebrae, as follows: 1. Posterior instrumenta-
tion (PI); 2. Anterior instrumentation and anterior col-
umn reconstruction with use of a titanium cage (AIAC);
3. Posterior instrumentation and anterior column recon-
struction with use of a titanium cage (PIAC); 4. Anterior
instrumentation and anterior column reconstruction
with use of chest tubes filled with bone cement (AIABc)
(Fig. 1). We placed the vertebra models as if the patient
was lying in supine position. We delineated the target
volume as the spinous process and lamina of the lumbar
(L) 3 vertebra in compliance with the definition in
RTOG 0631 study [12]. We used the titanium CD Hori-
zon Legacy 5.5 (Medtronic Sofamor Danek, Minneapolis,
Minnesota USA) for posterior instrumentation, the CD
Horizon Antares system (Medtronic Sofamor Danek,
Minneapolis, Minnesota, USA) for anterior instrumenta-
tion, the Pyramesh (Medtronic Sofamor Danek, Minneap-
olis, Minnesota, USA) for vertebral body replacement, and
polymethylmethacrylate cement (Surgical Simplex P, How-
medica, Limerick, Ireland).
To simulate the soft tissue around the vertebrae these
models and a standard sawbone were placed in water
separately. CT images (1.25-mm thick) of the sawbones
placed in water were obtained using a GE High-Speed
NX/I CT simulator (GE Medical System, Milwaukee WI,
USA). Before performing each CT scan, a 4.5x0.89 mm
thermoluminescent dosimeter (TLD, LiF:Mg,Ti) was
placed in the space between the spinal cord and the
posterior border of the vertebral body, just anterior to
the structure representing the spinal cord so as only
to define the point of measurement in the CT slices
and to determine the exact dose at that point in the
treatment planning system (TPS) (Fig. 2). This TLD
was used only to guide us to measure the point dose
at and around that point in the TPS. The target at
the spinous process and lamina of the L3 vertebra
was delineated according to the Radiation Therapy
Oncology Group (RTOG) 0631 trial protocol when
the metastasis involved only the posterior element
[12]. The spinal cord was also delineated as the organ
at risk (OAR). To obtain a homogenous dose distri-
bution around the point of measurement we defined
the TLD with a 0.5-cm margin in all directions as a
structure. The planning CT (GE BrightSpeed 16 Slice
CT, GE HealthCare, USA) does not have a software
for metal artifact reduction, so we did not perform
any compensation for metal artifacts.
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Treatment Planning
We used MultiPlan (Accuray Inc., Sunnyvale, CA, USA)
inverse planning software for treatment planning and
the prescription dose was 8 Gy. The treatments were
administered in a single fraction using a CyberKnife®
(Accuray Inc., Sunnyvale, CA, USA) (Figs. 3 and 4). For
anterior instrumentation models 2 different plans were
performed. In plan A beam interaction between the en-
tering beams and the rod was not limited. In plan B the
rod was considered a structure of avoidance and inter-
action between the rod and the entering beam was
prevented. The TLDs used during the irradiation were
different from the ones used during the CT scan. To
minimize the potential error due to the localization of
the TLD chips and dose gradients, we gave constraints
to the TLD with a 0.5-cm margin around it. A region
covered by 2 Gy with a 1.25 homogeneity index (HI) was
obtained in 3 dimensions. Homogeneity index was de-
fined as the maximum dose within target volume/pre-
scribed dose, as proposed by RTOG [13]. As the TPS in
the CyberKnife® does not allow to set a density override
on metal artifact-affected regions, we did not perform
any compensation for metal artifacts during treatment
planning.
TLD calibration
TLD 100 chips were calibrated with 2 Gy to a field of
10 cm × 10 cm with Varian Clinac DHX High Perform-
ance linear accelerator (Varian Medical Systems, Inc.,
Palo Alto, CA) using 6 MV photons, as this process is
not practical with a CyberKnife® [14]. In total, 101 TLDs
were placed in a specially designed water equivalent
Fig. 1 Spinal implant reconstruction models on the standard sawbones of lumbar vertebrae. 1. PI: Posterior instrumentation. 2. AIAC: Anterior
instrumentation and anterior column reconstruction with use of a titanium cage. 3. PIAC: Posterior instrumentation and anterior column
reconstruction with use of a titanium cage. 4. AIABc: Anterior instrumentation and anterior column reconstruction with use of chest tubes filled
with bone cement
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Fig. 2 a and b. TLD (Thermoluminescent dosimeter) placement in the AIAC model. Figure 2A shows the axial and 2B shows the sagittal views
in treatment position. The arrow shows the TLD behind the vertebral body, anterior to the spinal cord. The blue-outlined and orange-outlined
structures represent the spinal cord and rods, respectively. The red structure represents the target volume. The orange, yellow and pink lines
represent 80 %, 60 %, and 50 % isodoses respectively
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phantom (PMMA). Calibration factors were defined
for each TLD.
Dose measurement
The TLDs were encapsulated with paper and water proof
tape in order to prevent them from the effects of water
and other environmental factors. Each TLD location was
labeled by a letter-number couple and irradiated. Pencil
beam algorithm was used for dose calculation. Measure-
ments were performed 3 times, and the mean was calcu-
lated. The annealing process started with annealing at
400 °C for 1 hour and 100 °C for 2 hours prior to irradi-
ation, and preheating at 140 °C for 10 seconds and heat-
ing up to 280 °C at a rate of 5 °C s-1 after following
Fig. 3 a (1,2) and b. The treatment plans of AIAC (3A1 and 3A2) and PIAC (3B); above: sagittal view, below: transverse view. Figure 3A1 and A2
shows the AIAC model with the interaction between the entering beams and rods blocked and unblocked, respectively. In Figure 3A1 and A2;
yellow: spinal cord, red: target volume, cyan: 80 % isodose line, pink: blocked rod. In Fig. 3B; yellow: spinal cord, red: target volume, orange: 100 %
isodose line
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irradiation, the same way as Bassinet et al. performed
(12). The results were compared with the point dose cal-
culated by the TPS. The following formula was used to
calculate variations in dose by percentage:
DoseTLD– DoseTPS½ =DoseTPS;
where DoseTLD is the dose measured at each TLD in
each model and DoseTPS is the dose calculated by
the TPS.
Results
Mean doses administered to the TLDs, the TPS-
calculated dose, and differences between them are
shown in Table 1. TLD measurements and the TPS dose
differed by 1.7, 2.8, and 2.7 % for the sawbone model
with no implant, the PI model, and the PIAC model,
respectively. These findings show that the titanium cage
had a minimal effect on dose distribution, as the
percentages of difference corresponded to the clinical
acceptability range of ±5 % [15]; therefore, beam inter-
action with the cage was not limited—that is to say the
cage was not blocked. For the AIAC model the TLD
dose was 13.8 % higher than the TPS dose. Furthermore,
the difference was 18.6 % for the AIABc model. Taking
these dose differences into consideration, the rods were
blocked for plan B. In plan B for the AIAC and AIABc
models the TLD doses were 2.5 and 0.9 % higher, re-
spectively, than the TPS dose. Blocking the rods reduced
the percentage of difference between TLD measure-
ments and the TPS dose.
Discussion
SBRT for the spine has been used at RT clinics in pa-
tients with spinal metastases with increasing frequency.
The spinal cord dose constraint for SBRT is defined as
10 Gy in a single fraction, and because of the possible
devastating results of a spinal cord overdose, this con-
straint is strictly followed. In the present study the effect
of spinal implants on the spinal cord dose during SBRT
Fig. 4 a and b. The axial view of the entering beams in AIAC
models shown in Figure 3A1 and A2. Light blue rays are beam-on
and dark blue rays are beam-off treatment positions, respectively.
Figure 4A and B show the entering beams with the interaction
between beams and rods blocked and unblocked, respectively
Table 1 TLD and TPS doses for each model
Models TPS dose (cGy) 1st measurement (cGy) 2nd measurement (cGy) 3rd measurement (cGy) Mean Difference (%)
No implant 230 233 234 236 234 1.7
PI 245 235 263 258 252 2.8
PIAC 220 207 224 218 216 2.7
AIAC 230 254 264 270 262 13.9
AIAC- Plan B 235 235 225 228 229 2.5
AIABc 350 418 414 413 415 18.6
AIABc-Plan B 230 234 227 236 232 0.9
TLD Thermoluminescent dosimeter, TPS, Treatment planning system, PI posterior instrumentation, AIAC anterior instrumentation and anterior column
reconstruction with use of a titanium cage, PIAC posterior instrumentation and anterior column reconstruction with use of a titanium cage, AIABc anterior
instrumentation and anterior column reconstruction with use of chest tubes filled with bone cement
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for the treatment of spinal metastases was evaluated
using morphologic replicas of vertebrae and implants
that can be seen in patients in routine practice, and
spinal cord doses ≤18.6 % higher than TPS doses were
observed.
Patients with an impending fracture or a pathologic
fracture, spinal instability, progressive spinal cord
compression (SCC), progressive spinal deformity, or re-
current symptoms following RT require surgical inter-
vention [16, 17]. Spinal cord compression is observed in
approximately 20 % of patients with vertebral body me-
tastases [18]. In cases of collapsed vertebral bodies ver-
tebroplasty is the treatment of choice. Several types of
surgical techniques can be used for vertebral body
stabilization. Instrumentation with a rod can be per-
formed posteriorly or anteriorly with a cage—with or
without anterior column reconstruction. Patchell et al.
[19] compared surgery to RT alone in patients with SCC,
and reported that surgery was superior to RT for all end-
points, such as fecal continence, overall survival, and the
need for pain killers. The combination of surgery and
RT resulted in a greater likelihood of walking in patients
who were paraplegic prior to surgery. Even partial resec-
tion of spinal metastasis increased the effectiveness of
RT [19]. Ghogawala et al. [20] reported that wound
complications occurred more frequently when surgery
followed RT, as compared to when surgery was per-
formed prior to RT (32 % vs. 12 %) ; therefore, surgery
followed by RT is the recommended treatment for pa-
tients with SCC [19].
The most important problem with postoperative RT is
radiation scatter due to implants. As implants are made
of high atomic number materials, such as titanium, they
cause dosimetric uncertainty due to beam attenuation
and scatter [21]. The dosimetric effect of hip implants in
pelvic RT has been studied. Bahreyni Toossi et al. [22]
studied electron and neutron contamination of 4 differ-
ent hip prosthesis varying in composition, including
cobalt-chromium-molybdenum, stainless steel, titanium-
alloy, and titanium. They observed an increase in elec-
tron and neutron contamination in all 4 implants. On
the other hand, Schneider et al. measured neutron doses
owing to titanium-alloy prostheses during photon and
proton therapy and found no impact of prostheses on
neutron contamination [23]. In another study based on
6 MV photons, dose inhomogeneity of 10 % was calcu-
lated in the vicinity of the implant, whereas in areas
away from the implant dose homogeneity was within
5 % of the prescribed dose [24].
The American Association of Physicists in Medicine
(AAPM) Task Group 63 published a report to inform
the radiation oncology community of the problems asso-
ciated with metal implants in the treatment field, and
provide recommendations related to treatment planning
and delivery in patients with hip prostheses [21]. They
proposed beam arrangements that completely or par-
tially avoided prostheses; however, what was proposed
had the potential to increase the dose to the OARs.
There are also dosimetric studies performed with
spinal implants. Wang et al. [25] performed a dosimetric
study based on small fields ranging from 2x2 to 5x5 cm,
and used 5-mm thick titanium rods embedded in water.
They reported that the dose was 6 % higher at the inter-
section point of the rod and water due to backscattered
electrons, and was 7 % lower in the shadow of the rod
because of photon attenuation. Liebross et al. [26] stud-
ied the dose perturbation of screws and rods used for
spinal implants. They used a 20x20-cm field and ob-
served a dose reduction behind the rods. Son et al. [27]
measured doses in the space between 2 titanium screws
and reported the dose was 1.9 % lower, as measured via
an ionization chamber.
The spatial relationship that parts of implants have
with each other and with the OARs was not taken into
consideration in the studies mentioned above. To over-
come this limitation Pekmezci et al. performed 4 spinal
implant reconstructions in sawbone spine models to
evaluate the effects of implants on dose distribution for
a single field (postero-anterior) technique using a cobalt-
60 unit and a 6-MV linear accelerator [28]. Posterior
instrumentation resulted in a 5 % lower dose, whereas
the anterior instrumentation models did not have a
significant effect on dose distribution.
The CyberKnife® is an image-guided stereotactic radio-
surgery and SBRT device that facilitates tumor treatment
by generating a large number of direction points
(typically 1000-6000); however, use of a high number of
beams at different angles causes complex interactions
between each beam and the implants. We hypothesized
that these complex interactions between beams and im-
plants may cause an unpredictable and totally different
dosimetric effect than the interactions between beams
and implants that occur with conventional treatment
plans. It has been shown that the TPS generally calcu-
lates wrong dose values in the vicinity of metal artifacts.
This led to a standard procedure of setting the density
to a value that would correspond to the soft tissue ob-
scured by the artifacts during treatment planning [29].
However, as both our planning CT and the TPS of
CyberKnife® do not allow this option, we could not per-
form any compensation for the metal artifacts.
During stereotactic RT treatments in CyberKnife® pa-
tients are usually treated in supine position, and this de-
vice allows beam delivery from the anterior and lateral
directions. Therefore, the anterior rod placement in this
position results in an interaction between the rod and
entering beams. However, in posterior instrumentations
the rods are located in the path of exit beams. The
Yazici et al. Radiation Oncology  (2016) 11:71 Page 7 of 9
present findings show that the interaction with the en-
tering beams caused unacceptably high spinal doses.
Furthermore, use of a titanium cage or chest tubes filled
with cement placed anterior to the spinal cord did not
have a significant dosimetric effect. This observation
provides a guide in clinical practice because describing
all implants as structure of avoidance according to the
AAPM task group’s recommendation limits the angles
that can be used with SBRT profoundly. Limiting the
number of angles can result in unacceptably high doses
in the adjacent organs. Based on the present findings, we
suggest that only rods—when placed anterior to the
spinal cord—should be considered structures of avoid-
ance when using a TPS to calculate the absorbed dose.
Conclusions
Spinal implants may be present in the treatment field in
patients scheduled to undergo SBRT. For the types of
implants studied herein anterior rod instrumentation re-
sulted in an increase in the spinal cord dose, whereas
use of a titanium cage had a minimal effect on dose dis-
tribution. While planning SBRT in patients with spinal
reconstructions, avoidance of the rod and preventing
interaction between rod and entering beam might be the
optimal solution for preventing unexpectedly high spinal
cord doses.
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